Hetero Drugs Limited, a active public limited company, was established on 06 April 1993 in Hyderabad, Telangana, India. Engaging in api manufacturers within the manufacturing sector, it holds CIN: U24230TG1993PLC015582. Registered under ROC Roc Hyderabad. it is unlisted. It has an authorized capital of ₹10.00 Cr and a paid-up capital of ₹3.45 Cr.
Formerly known as Hetero Drugs Private Limited. It upholds a compliant status. Employing 1,711 professional, Its leadership includes Bandi Vamsikrishna (Director), Adisesha Giri Jagarapu (Director), Parthasaradhi Reddy Bandi (Director). Past directors included Gopala Krishna Rampalli, Bandi Vamsikrishna, Adisesha Giri Jagarapu. It holds ₹954.50 Cr open charges and ₹3,713.38 Cr settled loans. Its latest AGM occurred on 28 September 2024, with the balance sheet filed on 31 March 2024. It is based at #7-2-A2, Industrial Estate, Sanathnagar,, Hyderabad, Telangana, 500018.
U24230TG1993PLC015582
015582
06 April 1993
₹10.00 Cr
₹3.45 Cr
Roc Hyderabad
Unlisted
Active
Explore comprehensive insights into Hetero Drugs Limited — covering financial performance, compliance records, Competitor, shareholding patterns, directors, key metrics, and litigation history. Unlock to see detailed insights and stay informed.
Access Report
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Bandi Vamsikrishna | Director | 10 Apr 2008 | Current |
| Adisesha Giri Jagarapu | Director | 23 Sep 2021 | Current |
| Parthasaradhi Reddy Bandi | Director | 01 Apr 2008 | Current |
| Attunuri Venkatanarasa Reddy | Director | 28 Jan 1999 | Current |
| Kalavathi Bandi | Director | 01 Apr 2015 | Current |
| Gopal Reddy Annareddy | Director | 21 Dec 2023 | Current |
| Name | Designation | Cessation | Status |
|---|---|---|---|
| Pramod Abcsdd | Additional Director | 28 Sep 2017 | Past |
| Pramod Abcsdd | Additional Director | 25 Sep 2008 | Past |
| Pramod Abcsdd | Additional Director | 25 Nov 2021 | Past |
| Pramod Abcsdd | Company Secretary | 17 Feb 2024 | Past |
| Pramod Abcsdd | Additional Director | 28 Sep 2017 | Past |
| Pramod Abcsdd | Company Secretary | 02 Jul 2025 | Past |
Discover detailed profiles of directors and KMP - Unlock leadership insights today!
Hetero Drugs Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 19.76% increase. The company also saw a substantial improvement in profitability, with a 65.07% increase in profit. The company's net worth moved up by a moderate rise of 8.05%.
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
In 2023, Hetero Drugs had a promoter holding of 76.24% and a public holding of 23.76%. The company had 5 Subsidiaries and 3 Associate Companies. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Reveal ownership structures and financial performance - Get instant access now!
₹9,544,983,602.00
₹37,133,800,000.00
| Date | Lender | Amount | Status |
|---|---|---|---|
| 04 Sep 2025 | Bank Of India | ₹1.40 M | Open |
| 04 Sep 2025 | Bank Of India | ₹1.05 M | Open |
| 01 Sep 2025 | Bank Of India | ₹0.80 M | Open |
| 22 Aug 2025 | Bank Of India | ₹1.49 M | Open |
| 29 Jul 2025 | Bank Of India | ₹0.90 M | Open |
Explore comprehensive loan charge details -
Hetero Drugs has a workforce of 1711 employees as of Jul 30, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Gain comprehensive insights into the Deals and Valuation data of Hetero Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Hetero Drugs's trajectory.
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
The activity A charge with Bank Of India amounted to Rs. 0.14 Cr with Charge ID 101163398 was registered on 04 Sep 2025. was completed.
The activity A charge with Bank Of India amounted to Rs. 0.11 Cr with Charge ID 101163367 was registered on 04 Sep 2025. was completed.
The activity A charge with Bank Of India amounted to Rs. 0.08 Cr with Charge ID 101156685 was registered on 01 Sep 2025. was completed.
A charge with Bank Of India amounted to Rs. 0.15 Cr with Charge ID 101156680 was registered on 22 Aug 2025. was recorded as a recent event.
The activity A charge with Bank Of India amounted to Rs. 0.09 Cr with Charge ID 101152413 was registered on 29 Jul 2025. was completed.
Progress on A charge with Bank Of India amounted to Rs. 0.09 Cr with Charge ID 101145830 was registered on 29 Jul 2025. was documented.
Hetero Labs recalls losartan potassium tablets due to presence of N-Nitroso-N-methyl-4-aminobutyric acid..
The U.S. Food and Drug Administration is also looking into whether these types of impurities could be found in other classes of drugs, a spokeswoman for the regulator said..
/PRNewswire/ -- Camber Pharmaceuticals, Inc. is recalling 87 lots of Losartan Tablets USP 25 mg, 50 mg, and 100 mg to consumer level. This recall was prompted....
Drug firm Hetero Friday said it has launched generic Lapatinib tablets, used in the treatment of advanced or metastatic breast cancer in the country..
The acquisition enables Hetero with a strong front-end marketing presence giving Amarox the required commercial infrastructure, product portfolio, manpower and a seamless entry into the Retail, Hospital and Tender business channels in Spain..
The CIN of Hetero Drugs Limited is U24230TG1993PLC015582.
Hetero Drugs Limited is headquartered at #7-2-A2, Industrial Estate, Sanathnagar,, Hyderabad, Telangana, 500018.
Hetero Drugs Limited was incorporated on 06 April 1993.
The current directors of Hetero Drugs Limited are
The primary industry of Hetero Drugs Limited is Manufacturing.
Hetero Drugs Limited is unlisted.
The authorized capital of Hetero Drugs Limited is ₹10.00 Cr, and the paid-up capital is ₹3.45 Cr.
The compliance status of Hetero Drugs Limited is Compliant.
Search company & director profiles for free and gain access to critical business data.
Company Details
+91-XXXXXXXXXX